Distinction between fetal growth restriction and small for gestational age newborn weight enhances the prognostic value of low PAPP-A in the first trimester

Prenatal Diagnosis

Volumn 30, Issue 10, 2010, Pages 1007-1009

  Conserva, V ^a   Signaroldi, M ^a   Mastroianni, C ^a   Stampalija, T ^a   Ghisoni, L ^b   Ferrazzi, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CEO Bi Tech Ltd   (Italy)

Author keywords

Fetal and placental pathology; Fetal growth restriction; Maternal serum screening; Nuchal translucency; PAPP A; Small for gestational age

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A;

BODY WEIGHT; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LETTER; MATERNAL SERUM; MATERNAL SMOKING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; PROGNOSIS; SMALL FOR DATE INFANT;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; ITALY; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY, HIGH-RISK; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PREMATURE BIRTH; RETROSPECTIVE STUDIES;

EID: 77957367392     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2579     Document Type: Letter

References (12)

1. Barrett SL, Bower C, Hadlow1 NC. 2008. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn 28: 28-35. (Pubitemid 351251986)
2. Breslow NE, Day NE. 1980. Statistical Methods in Cancer Research, vol I. The Analysis of Case-control Studies. World Health Organization - International Agency for Research on Cancer: Lyon. IARC Scientific Publications 32: 5-338.
3. Davey DA, MacGillivray I. 1988. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 158: 892-898.
4. Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 191: 1446-1451.
5. Goldenberg RL, Culhane JF, Iams JD, et al. 2008. Epidemiology and causes of preterm birth. Lancet 371(9606): 75-84.
6. Kavak ZN, Basgul A, Koray E, et al. 2006. The efficacy of first-trimester PAPP-A and free βhCG levels for predicting adverse pregnancy outcome. J Perinat Med 34: 145-148.
7. Krantz D, Goetzl L, Simpson JL, et al. 2004. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191: 1452-1458.
8. Poon LCY, Stratieva V, Piras S, Piri S, Nicolaides KH. 2010. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 30: 216-223.
9. Smith GCS, Shah I, Crossley JA, et al. 2006. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 107: 161-166.
10. Snijders RJ, Noble P, Sebire N, et al. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125): 343-346. (Pubitemid 28352196)
11. Spencer CA, Allen VM, Flowerdew G, et al. 2008a. Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes Prenat Diagn 28: 1029-1036.
12. Spencer K, Cowans Nj, Molina F, et al. 2008b. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 31: 147-152.